Platform Life Sciences, a high impact Clinical Research Organization, with the mission to modernize clinical trials on a global scale, has signed a key agreement with GreenLight Biosciences to support their Phase I clinical trial, GLB-003, for a novel mRNA vaccine against COVID-19 in Rwanda – that today has been approved by the Rwanda FDA. The trial will be performed…
UBC faculty of medicine researchers have been awarded federal funding as part of Canada’s largest-ever investment in clinical trials. The Canadian Institutes of Health Research Clinical Trials Fund (CTF) dedicated $250 million across three funding streams to grow and strengthen Canada’s clinical trials infrastructure, training, and research through 2025. Approximately $60M is being awarded to 22 projects to fund clinical trial phases, designs,…
Congratulations to the successful applicants in the CIHR Fall 2022 Project Grant competition! Listed below are the LSI-based PIs on the six funded projects. These include one bridge grant and one Priority Announcement Grant. This amounts to 21.4% of submitted applications receiving funds to a total of $3.77 million from this competition, where overall funding rate was 20% and British Columbia’s success…
As Canadian policy and investment encourages more innovative startups, we constantly hear about the “valley of death”: the point where a startup has some momentum but struggles for market traction. We hang lofty hopes on research-based startups getting past this to solve global challenges and grow into scalable companies. However, focusing on the valley of death will keep us ignoring…
The Canadian Institutes of Health Research (CIHR) has announced the results of its Fall 2022 project grant competition. Congratulations to all the VCHRI researchers who were awarded project grants and priority announcement grants. Deconvoluting Prognostic and Targetable Features of Endometrioid Ovarian Carcinomas of No Specific Molecular Profile Principal Investigators: Dr. Michael Anglesio, Dr. Aline Talhouk
Binding of USF1/2 and TFII-I (RBF-2) at conserved sites flanking the HIV-1 LTR enhancer is essential for reactivation from latency in T cells, with TFII-I knockdown rendering the provirus insensitive to T cell signaling. We identified an interaction of TFII-I with the tripartite motif protein TRIM24, and these factors were found to be constitutively associated with the HIV-1 LTR. Similar to…
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Zymeworks Inc. (Nasdaq: ZYME) today announced tolerability and efficacy results, including the first overall survival (OS) data, from a Phase 2 trial examining zanidatamab, an investigational HER2-targeted bispecific antibody, in combination with chemotherapy, in first-line patients with HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA). The preliminary results showed that, at the time of analysis, the median OS had not…
Melanoma is a malignant tumor that accounts for the deadliest form of skin cancers. Despite the significant efforts made recently for development of immunotherapeutic strategies including using immune checkpoint inhibitors and cancer vaccines, the clinical outcomes are unsatisfying. Different factors affect efficient cancer immunotherapy such as side-effects, immunosuppressive tumor microenvironment, and tumor heterogeneity. In the past decades, various nanotechnology-based approaches…
UBC evolutionary biologist Dr. Dolph Schluter has been awarded the Crafoord Prize in Biosciences by the Royal Swedish Academy of Sciences (RSAS) and the Crafoord Foundation for his research into the role of natural selection in adaptive radiation and the origin of species. The Crafoord Prize, which includes 6,000,000 Swedish krona ($780,000 CAD) to fund further research by the winner,…
Dr. Sophia Frangou received a Djavad Mowafaghian Centre for Brain Health Alzheimer Disease Research Grant to use large-scale datasets to identify environmental factors that can accelerate or delay brain aging. See which other Vancouver researchers received grants, awards, scholarships, and fellowships in January.
